Economic impact of a drug information service

Annals of Pharmacotherapy

Volumn 33, Issue 1, 1999, Pages 11-16

  Kinky, Denise E ^a   Erush, Sarah C ^b   Laskin, Mitchell S ^b   Gibson, Gene A ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

Cost; Drug information

Indexed keywords

ARTICLE; COST CONTROL; DISEASE SEVERITY; DRUG INFORMATION; MEDICAL DECISION MAKING; MODEL; PHARMACY; PRIORITY JOURNAL; RATING SCALE;

COST SAVINGS; DRUG INFORMATION SERVICES; HUMANS; MODELS, ECONOMIC;

EID: 0032950968     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18218     Document Type: Article

References (6)

1. Lyrvall H. Nordin C. Jonsson K. Alvan G. Potential savings of consulting a drug information center (letter). Ann Pharmacother 1993:27:1540.
2. Strand LM, Morley PC. Cipolle RJ. Ramsey R. Lamsam GD. Drug-related problems: their structure and function. DICP Ann Pharmacother 1990:24:1093-7.
3. Nadzam DM. Development of medication-use indicators by the Joint Commission on Accreditation of Healthcare Organizations. Am J Hosp Pharm 1991:48:1925-30.
4. Johnson JA. Bootman L. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995:155:1949-56.
5. Schneider PJ. The costs of adverse drug events. US Pharmacist 1996; (October supp 1): 18-21.
6. McGhan WF. Kitz DS,. Cost-benefit analysis. In: Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics, 2nd ed. Cincinnati: Harvey Whitney Books Company. 1996:61-75.